C&EN

Chemical & Engineering News (C&EN) is a weekly publication produced by the American Chemical Society, offering valuable insights and updates in chemistry and chemical engineering. The magazine covers a wide range of topics, including the latest news and research, job opportunities, industry developments, government policies, and funding information. Both the print and digital editions are accessible to those with a national membership in the American Chemical Society. Additionally, the front section of the magazine is available online for free, while a subscription is necessary to access the complete content. Readers can also find exclusive online features and searchable archives of past issues.

National, Trade/B2B

English

Magazine

Outlet metrics

Domain Authority

Ranking

Global

N/A

Country

N/A

Articles

US FDA approves Moderna's next-generation COVID-19 vaccine, with caveats

5 days ago | cen.acs.org | Rowan Walrath

The US Food and Drug Administration has greenlit a next-generation COVID-19 vaccine from Moderna that's engineered to be given in a smaller dose than the current one and targets certain portions of the SARS-CoV-2 spike protein. But only certain groups are approved to get the new vaccine. The FDA approved mRNA-1283, marketed under the name mNEXSPIKE, for all adults 65 and older and 12- to 64-year-olds with at least one condition that puts them at risk for severe outcomes of COVID-19.
Huntsman, Sasol, and biofuel makers eye European plant closures

1 week ago | cen.acs.org | Alex Scott

More chemical companies say they will-or may-close plants in Europe because of tough economic circumstances. The announcements follow a series of plant closures already announced in Europe this year. Huntsman says it will close its facility in Moers, Germany, for making maleic anhydride-a precursor for unsaturated polyester resins-by the end of June. The business generated a pretax loss of $10 million in 2024. The company will write down $75 million because of the closure.
Syndeio Biosciences launches with molecules to target the synapse

1 week ago | cen.acs.org | Sarah Braner

With $90 million in funding, Syndeio Biosciences has launched to target synaptopathies. These diseases and disorders, such as Alzheimer's disease and major depressive disorder, are thought to result from damaged neural networks. In addition to cash, the company has several assets in hand, including a lead drug candidate, zelquistinel, that is currently in Phase 2 clinical trials to treat major depressive disorder.
Honeywell to buy Johnson Matthey's catalyst technology unit

2 weeks ago | cen.acs.org | Alexander H. Tullo

Honeywell International has agreed to purchase Johnson Matthey's catalyst technologies business for about $2.3 billion. It plans to combine the business with its UOP subsidiary to create a chemical process engineering and catalysis giant. Johnson Matthey's catalyst business generated $930 million in sales during the company's most recent fiscal year.
2025 Talented 12: Shira Joudan

2 weeks ago | cen.acs.org | Michael Torrice

Trifluoroacetic acid is a contaminant that likes to move around. Scientists have found the chemical, known as TFA, in the deep ocean, in the Arctic, in plants, and in our blood. TFA also doesn't biodegrade, so it persists in the environment. But unlike many other persistent pollutants, TFA has few direct sources. Most comes from reactions involving other contaminants. Shira Joudan identifies and studies these reactions to find out exactly where TFA is coming from.
Pilanda Watkins-Curry

2 weeks ago | cen.acs.org | Matt Blois

Pilanda Watkins-Curry keeps a chessboard on her coffee table at home. She started playing with her father and grandfather when she was 5 years old. Now, playing with her family gives her a chance to focus her analytical mind on an orderly puzzle and block out the chaos that comes with founding a chemistry start-up. In 2021, Watkins-Curry cofounded Olokun Minerals, where she serves as chief technology officer and leads R&D.
2025 Talented 12: Sascha Feldmann

2 weeks ago | cen.acs.org | Mark Peplow

For a chemistry undergraduate focused on synthesis, pivoting to a PhD in physics is a bold move. But that's exactly what Sascha Feldmann did-unlocking a research career that fuses materials science, photonics, and quantum physics. Feldmann's group at the Swiss Federal Institute of Technology, Lausanne (EPFL), probes the fundamentals of light, charge, and symmetry to boost solar photovoltaics, build energy-efficient electronics, and develop quantum information technologies.
2025 Talented 12: Dayne Swearer

2 weeks ago | cen.acs.org | Mark Peplow

For Dayne Swearer, electrons have power-literally. At Northwestern University, his team uses the kinetic energy carried by "hot" electrons to drive some of the world's most important industrial chemical reactions. Powered by renewable electricity, this approach could offer a cleaner route to staples like hydrogen and ammonia than traditional thermal processes that depend on fossil fuels.
2025 Talented 12: Tejas Shah

2 weeks ago | cen.acs.org | Sam Lemonick

"When I was applying for jobs, I had no idea there was a field of agrochemistry," Tejas Shah says. At the suggestion of his graduate adviser, Shah applied for an opening at what is now Corteva Agriscience, which makes chemicals for farming. He has spent the last decade with the company, where he created its first chemistry automation and high-throughput experimentation group and used computational tools to find a small-molecule herbicide with a new mode of action.
The US is ditching a one-size-fits-all approach to COVID-19 vaccines. Here's what new guidance means

2 weeks ago | cen.acs.org | Rowan Walrath

US residents' ability to get COVID-19 vaccines this fall is about to change as US Food and Drug Administration leaders shift away from a one-size-fits-all approach, raising concerns among vaccine researchers. Under new guidance this week from the FDA's top brass, annual COVID-19 boosters will be authorized only for people 65 years old and older, as well as people with certain health risks, including asthma and diabetes (N. Engl. J. Med. 2025, DOI: 10.1056/NEJMsb2506929).